ACTG A5224s was a substudy of A5202 , which randomly assigned ART-naive HIV-infected subjects to blinded abacavir/lamivudine ( ABC/3TC ) or tenofovir/emtricitabine ( TDF/FTC ) with open-label efavirenz ( EFV ) or ritonavir-boosted atazanavir .